top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese...
Jul 21, 20213 min read
Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
Demonstrating Advancement in the Company’s Technology to Treat Diabetes Ness Ziona, Israel, May 11th, 2021, Kadimastem (TASE: KDST), a...
May 11, 20213 min read
Kadimastem Raises NIS 22.3 Million ($6.8 Million)
Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement Institutional investors Alpha Capital Anstalt and...
Apr 26, 20213 min read
Kadimastem Granted a Patent in Israel for the Treatment of ALS
Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use...
Mar 9, 20213 min read
Kadimastem Announces Executive Management Changes
Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO Company Appoints Biotech Industry Leaders Ronen Twito, CPA...
Jan 31, 20215 min read
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
No treatment-related serious adverse events nor dose-limiting toxicities were reported during the 6- month post-treatment follow up...
Dec 15, 20205 min read
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in
AstroRx® demonstrated to be safe and well tolerated in the higher treatment dose Clinically meaningful decline in disease progression...
Aug 3, 20207 min read
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
No treatment-related serious adverse events nor dose-limiting toxicities were reported A statistically significant decline in disease...
Jan 2, 20207 min read
Kadimastem Announces the Completion of Treatment for Cohort B
The patients in this Cohort were treated with a single dose of 250x106 cells of AstroRx® The clinical trial continues as planned. Cohort...
Dec 23, 20194 min read
Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes
Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time Unique technology...
Nov 19, 20194 min read
Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol
Following Recent Positive Interim Results The Company intends to assess the safety and efficacy of a repeated administration of the low...
Nov 17, 20194 min read
Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv
Kadimastem to Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in...
Nov 11, 20193 min read
Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Disease progression was reduced in the first 3 months post-treatment period compared to the 3 months pre-treatment period, this...
Sep 24, 20195 min read
Kadimastem Announces Leadership Changes
NESS ZIONA, Israel, May 29, 2019 Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef...
May 20, 20192 min read
Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®
Ness Ziona, Israel, April 18th 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval from the MOH of...
Apr 18, 20192 min read
Appointment of a new CFO for Kadimastem
The Current CFO has accepted a position as the Director of the Budget Division of the Jewish Agency for Israel Ness Ziona, Israel, 3...
Mar 3, 20191 min read
Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A
Ness Ziona, Israel, 24 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of cell...
Feb 24, 20192 min read
2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project
Ness Ziona, Israel, 17 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announces it has received approval for its...
Feb 17, 20191 min read
Kadimastem to be included in the TASE Indices
Ness Ziona, Israel, November 27, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) received an announcement from the TASE, that...
Nov 27, 20181 min read
Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise...
Nov 14, 20181 min read
bottom of page